French pharmaceutical giant Sanofi announced on Wednesday (23) large-scale positive results from its anti-covid-19 vaccine, developed in partnership with the British laboratory GSK, after a year of tests and delays.
“Sanofi and GSK will apply for regulatory approval of their Covid-19 vaccine” in the United States and the European Union, both groups announced in a statement, after testing thousands of people.
Although the full studies have not yet been published, their results show that the drug contributes to preventing coronavirus-related hospitalization.
“We are confident that this vaccine can play an important role as we continue to address this pandemic and prepare for the post-pandemic period,” said GSK Vaccines President Roger Connor.
Initial data from the vaccine’s late-stage trial showed it was 100% effective against severe Covid-19 and hospitalization and 75% effective against moderate or severe disease. In addition, the vaccine would be slightly more than 50% effective for symptomatic Covid.
“No other global phase 3 efficacy study has been conducted during this period with so many variants of concern, including omicron, and these efficacy data are similar to recent clinical data from licensed vaccines,” said Thomas Triomphe, executive vice president of Sanofi. Vaccines.
If the vaccine is authorized, it will be the end of a long journey for both drug companies, who had hoped to be able to commercialize the drug by mid-2021.
The first obstacles arose with the correct dosage of the vaccine and, later, with the difficulty of finding people not yet infected, so that the tests were reliable.
Sanofi has had to abandon its attempts to create a vaccine based on the mRNA technology, which has been the basis of its competitors Pfizer/BioNTech and Moderna.
A Sanofi spokesperson reiterated the French drugmaker’s commitment to supply a total of 75 million doses to the European Union and Britain, as well as 100 million to the United States, pending regulatory approval.
Planned US deliveries would be governed by a $2.1 billion contract with the US government signed in July 2020, he added.
Chad-98Weaver, a distinguished author at NewsBulletin247, excels in the craft of article writing. With a keen eye for detail and a penchant for storytelling, Chad delivers informative and engaging content that resonates with readers across various subjects. His contributions are a testament to his dedication and expertise in the field of journalism.
